Medical Cannabis and the Issue of CBD Regulation in Poland: Quality, COA, Availability (2026)

You can buy the same chemical compound in Poland in three different ways, each overseen by a different authority. Cannabis flower on an Rpw prescription is a pharmaceutical raw material with a permit from the President of the Office for Registration of Medicinal Products. Store-bought oil may be a dietary supplement, a cannabis cream a cosmetic product, and industrial hemp flower a good whose status is not explicitly described by law. The difference lies not in cannabidiol chemistry but in the control regime. Below you will find what can be based on the text of the law or published studies: how the 0.3% threshold is calculated, what a prescription for flower requires, what a label audit published in JAMA showed, what dose EFSA considered temporarily safe in 2026, and what about the Polish market cannot be established at all today.

KEY INFORMATION
• 30.95% of 84 tested CBD products were label-compliant (Bonn-Miller, JAMA 2017).
• The 0.3% threshold applies to the plant, not the finished product, and is the sum of THC and THCA.
• EFSA in 2026 derived a temporary safe dose of about 2 mg daily for a 70 kg person.
• CBD safety cannot be established for people under 25, pregnant or breastfeeding women, and those taking medications.

Why is CBD regulation in Poland a problem for patients?

The problem arises because one ingredient falls under three separate legal regimes, each imposing different requirements on the manufacturer. Pharmacy flower is a pharmaceutical raw material with an office permit. Store oil is food or a cosmetic. Different inspections supervise these categories, none routinely testing every batch.

For the reader, this means a simple but inconvenient fact. Buying a pharmacy product, you pay partly for documentation: batch number, batch release, marketing authorization. Buying a supplement, you buy the manufacturer’s declaration, and verifying it depends solely on whether the seller voluntarily provides a certificate of analysis.

The second consequence concerns language. A supplement manufacturer cannot assign medicinal effects, so product descriptions revolve around general terms. The reader perceives them as therapeutic promises, though formally they are not. The gap between what is allowed on packaging and what buyers seek is constant in this category.

The third consequence is scientific, not legal. Even if the label perfectly matched the content, evidence for cannabidiol efficacy in most popular indications remains weak, and EFSA cannot currently establish safety of long-term use in several major groups. We discuss both below with specific studies.

What are medical cannabis and since when are they in Polish pharmacies?

Medical cannabis means cannabis other than industrial hemp and extracts and tinctures from this plant, approved as pharmaceutical raw material for magistral preparations. The basis is art. 33a of the Act on Counteracting Drug Addiction, and marketing requires a permit from the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, issued for five years.

The regulation was introduced by the Act of July 7, 2017 amending the Act on Counteracting Drug Addiction and the Act on Reimbursement (Journal of Laws 2017 item 1458), effective November 1, 2017. The date is sometimes shifted by a few months in cannabis texts, but the legal acts register states it clearly.

Pharmacy flower differs from store products not in cannabinoid content but in documentation and approval path. It is raw material for magistral preparations, not a finished consumer product, and cannot be bought without a prescription. We describe this category in more detail in the article about what medical marijuana is.

What does a prescription for cannabis flower require?

A prescription for a preparation containing cannabis other than industrial hemp can be issued only after a personal examination of the patient. This requirement is set by § 7 sec. 2a point 2 of the Minister of Health’s regulation on narcotic drugs and psychotropic substances (consolidated text Journal of Laws 2025 item 1678), and cannabis other than industrial hemp and cannabis resin are listed in Annex 2 to this regulation.

This is where guides often err. Teleconsultation is sometimes described as equivalent to an office visit, but the regulation treats it differently. The exception in § 7 sec. 2d applies to a primary care physician continuing already started treatment with this preparation and does not extend to the first prescription.

The amount of medicine is also limited. A prescription for a preparation containing a narcotic drug group I-N or psychotropic substance group II-P may cover up to 90 days of use (§ 7 sec. 1), and a doctor may issue up to three prescriptions for consecutive periods, together not exceeding 90 days (§ 7 sec. 2). Only one such preparation is prescribed per prescription.

The fulfillment period runs separately. A pharmacy must dispense a prescription for a narcotic drug group I-N or psychotropic substance group II-P no later than 30 days from the issue date (§ 10 sec. 1). The practical side of this process is described separately in the article about obtaining a medical marijuana prescription.

The regulation provides another narrower path. A prescription issued under art. 42 sec. 2 of the Act on the Profession of Physician and Dentist may concern such a preparation if no more than three months have passed since the last patient examination (§ 7 sec. 2b). The personal examination is recorded in medical documentation.

How to transport cannabis medicine across the border?

A separate document issued by the pharmaceutical inspection is required, not just the prescription. For export to another Schengen country, the relevant provincial pharmaceutical inspector issues it based on a certificate under art. 75 of the implementing convention. For import or export outside this area, the Main Pharmaceutical Inspector issues the document.

Deadlines are the same in both cases and derive from § 5 sec. 2 and § 6 sec. 2 of the Minister of Health’s regulation of June 8, 2026 (Journal of Laws 2026 item 827). The document is issued for a fixed period, no longer than 30 days, based on an application submitted no later than 15 days before crossing the Polish border.

The applicant is the person who personally takes the medicinal product and attaches the prescription or medical documentation confirming use. The document is issued on pink paper with security features for third-category public documents, and its electronic copy remains with the issuing authority.

The practical advice for patients is about timing, not legality. The 15-day advance application and 30-day validity mean trip planning starts at the inspectorate visit, not packing. The document covers transport for personal medical use and does not replace any commercial permit.

Does the 0.3% THC threshold apply to the product or the plant?

It applies to the plant. The law defines industrial hemp as Cannabis sativa plants in which the sum of delta-9-tetrahydrocannabinol and tetrahydrocannabinolic acid in flowering or fruiting tops, from which resin has not been removed, does not exceed 0.3% on a dry mass basis. The sum is rounded to one decimal place.

Two things in this sentence affect lab test results. First, the tested material is plant material, not finished oil, cream, or drink. Second, the sum of two compounds is counted, not just delta-9-THC. Tetrahydrocannabinolic acid converts to THC with heat, so labs measuring only the decarboxylated form report a value lower than the legal definition.

The basis is art. 4 point 5 of the Act of July 29, 2005 on Counteracting Drug Addiction (consolidated text Journal of Laws 2023 item 1939), as amended by the Act of March 24, 2022 (Journal of Laws 2022 item 763), effective May 7, 2022. Previously, the threshold was 0.20%, which still circulates in guides as valid.

The EU threshold has the same value but a different source: from January 1, 2023, varieties eligible for support under the Common Agricultural Policy may contain up to 0.3% THC under Regulation 2021/2115. The Polish threshold does not derive from this regulation but from national law. The correct statement is: the national threshold corresponds to the EU threshold. More on legality is in the guide to cannabis and CBD legality.

Are HHC and CBD controlled substances in Poland?

Cannabidiol is not listed as a controlled substance; hexahydrocannabinol is. We verified this in the consolidated text of the Minister of Health’s regulation on the list of psychotropic substances, narcotics, and new psychoactive substances (Journal of Laws 2024 item 1139): the word “cannabidiol” does not appear once in 83 pages.

HHC’s status changed on July 28, 2026. The Minister of Health’s regulation of July 7, 2026 (Journal of Laws 2026 item 934) repealed position 99 in group I-P and added hexahydrocannabinol as position 83 in group II-P. This is a transfer between groups, not removal from control: HHC remains controlled.

The same amendment restructured position 96 in group I-P, covering tetrahydrocannabinols. The new wording lists individual isomers and stereochemical variants, including delta-6a,10a-THC and delta-7-THC. The change direction is opposite to what some store descriptions suggest: the list is closing, not opening.

For the reader, this has one practical effect. The cannabinoid name on packaging does not indicate legal status, as regulations operate on a list of positions, not plant associations. Before buying a product with a semi-synthetic derivative, check its name in Annex 1 to the regulation, not in the offer description.

How much THC may food from hemp seeds contain?

Limits are expressed in milligrams per kilogram, not percentages, and this is a separate regulation from the 0.3% threshold. For hemp seeds and processed seed products, the maximum allowed level is 3.0 mg/kg, and for hemp seed oil 7.5 mg/kg. The basis is Annex I section 2.6 of Commission Regulation (EU) 2023/915, effective May 25, 2023.

The calculation method is the same as in the law but expressed differently. The level refers to the sum of delta-9-THC and delta-9-THCA, expressed as delta-9-THC, with a factor of 0.877 for the acid form. A producer testing only the decarboxylated form thus does not have a result comparable to the limit.

Mixing these two regimes is one of the most common errors in Polish cannabis texts. Hence the widespread formula about a 0.3% threshold for flower and 0.2% for extracts, which is not in any regulation. The 0.20% value applied in the law until May 6, 2022, and seed food limits were never expressed in percentages.

If you buy hemp seed oil as food, the proper question to the seller is the result in milligrams per kilogram, not a percentage copied from the plant description. Regulation 2023/915 replaced the earlier Regulation 1881/2006, to which hemp limits were added by Regulation 2022/1393.

Who in Poland may cultivate cannabis for pharmacy raw material?

The circle of entities is narrow and directly results from the law. Cultivation of cannabis other than industrial hemp is prohibited, except for cultivation under art. 49a, which allows it only for a research institute supervised by the minister responsible for agriculture, after obtaining a permit from the Main Pharmaceutical Inspector.

The permit is issued by decision upon application containing institute data, cultivation area and address, a statement on employing a person responsible for supervision of cultivation and harvest, and a statement on securing the cultivation site against unauthorized access. The application includes the institute’s statute and criminal record certificates of persons involved in cultivation and harvest.

The Main Pharmaceutical Inspector consults the Police unit competent for the cultivation location regarding security and keeps a register of issued permits. A separate fee of 1500 PLN for the permit application is specified in the law and does not depend on any intermediary’s price list.

While organizing this text, we noticed the most repeated inaccuracy online about Polish production is lists of private companies allegedly cultivating medical cannabis with permits. The law in force does not provide for this: the authorized entity is a research institute, not a business. Before repeating such a list, check art. 49a itself.

What do studies say about cannabinoid efficacy?

The strongest evidence concerns chronic pain and spasticity, and even these are moderate quality. The systematic review by Whiting et al. covered 79 randomized studies and 6462 participants. The authors rated evidence for chronic pain and spasticity as moderate quality, and for chemotherapy-induced nausea, weight gain in HIV, sleep disorders, and Tourette’s syndrome as low quality.

Numbers from this review should be read cautiously. Full response for nausea and vomiting was 47% versus 20% on placebo (odds ratio 3.82). Pain reduction was 37% versus 31%, but odds ratio 1.41 had a confidence interval from 0.99 to 2.00, thus not statistically significant. Cannabinoids were associated with increased risk of short-term adverse events, including serious ones (Whiting et al., JAMA 2015).

More recent and clearer are Cochrane findings. The 2026 update on cannabis preparations in neuropathic chronic pain included 21 studies and 2187 participants. For cannabidiol-dominant preparations, no clear evidence was found for 50% pain relief over placebo, with very low certainty. THC-dominant preparations had similarly inconclusive results and may increase nervous system adverse events (Ateş et al., Cochrane 2026).

An exception with strong results is drug-resistant epilepsy. In a double-blind study, 120 children and young adults with Dravet syndrome received cannabidiol 20 mg/kg/day or placebo for 14 weeks. Median seizure frequency dropped from 12.4 to 5.9 per month versus 14.9 to 14.1 on placebo. Diarrhea, vomiting, drowsiness, and abnormal liver tests were more frequent (Devinsky et al., NEJM 2017). This is a specific hospital study, not dosing guidance for readers.

Why is CBD product quality so uneven?

Because no one tests composition before market introduction. Testing every batch in an accredited lab is not a legal obligation for supplements or cosmetics, so declaration reliability depends on the manufacturer’s decision. The scale of discrepancy was first measured in 2017 and still shapes the quality discussion.

Bonn-Miller et al. bought 84 products from 31 online companies and tested actual cannabinoid content. Only 30.95% matched the label. 42.85% were under-labeled, 26.19% over-labeled. THC was detected in 18 of 84 samples (21.43%), with concentrations up to 6.43 mg/ml (Bonn-Miller et al., JAMA 2017).

Two caveats must be noted. Samples came from US online sales nearly a decade ago, not Polish stores. No percentage for today’s Poland can be derived, though such numbers circulate as facts. The takeaway concerns the mechanism: without batch testing, label declarations are promises, not measurements.

Also, the study did not measure metals, pesticide residues, or microbiology, so it does not address product purity. These parameters appear only in certificates of analysis, which are the only documents where you can see them.

How to read a CBD product certificate of analysis?

A certificate of analysis is a lab report for a specific batch, so first look for the batch number and test date. A document without a batch number describes some manufacturer sample, not necessarily the one on your shelf. Second, check if the lab is accredited and if its accreditation number can be verified with the accrediting body.

The cannabinoid profile is read together with acid forms. The manufacturer’s declaration usually concerns the sum of CBD and CBDA after decarboxylation, not CBD alone, so comparing the label with only one report item leads to a false conclusion of under-labeling. The same applies to THC and THCA, linking the certificate to the legal threshold definition.

The third report layer is contaminants. Cannabis absorbs metals from soil, and poorly dried plant material promotes molds, so a report without tests for metals, pesticide residues, microbiology, and extraction solvent residues says less about the product than it seems. Limits for hemp seed food are set by Commission Regulation (EU) 2023/915.

From client conversations, the most common problem is not lack of a certificate but mismatch. The document may concern raw material instead of finished oil, be several years old, or describe a different batch than purchased. If comparing offers before buying, our guide to CBD supplements in Poland is helpful.

What does novel food status mean for cannabidiol?

It means an authorization obligation before marketing, not a ban. The European Commission recognized cannabidiol as novel food under Regulation 2015/2283, so its introduction into food requires prior safety assessment and EU authorization. Until completion, food products with this ingredient remain in procedural suspension.

The scale of the procedure is often exaggerated in Polish texts. In a 2022 statement, the EFSA panel said it was assessing 19 applications, not hundreds. During evaluation, data gaps preventing safety conclusions were found, so the panel issued a separate opinion summarizing knowledge and indicating gaps (EFSA NDA Panel, EFSA Journal 2022).

Two reservations from that document reappear in the 2026 version. Most human data came from studies on drug-resistant epilepsy treatment, where adverse effects are accepted due to therapeutic benefit. Such a balance does not apply to food. These studies could not derive a dose without observed harmful effects.

The 2022 panel concluded that cannabidiol safety as novel food could not be established then. Four years later, the opinion was updated and for the first time included a numeric value, discussed below. A sanitary notification filed in Poland does not replace this procedure and does not change the ingredient’s status by itself.

What did EFSA establish about CBD safety in 2026?

The EFSA Panel on Nutrition and Novel Foods updated its opinion on cannabidiol as novel food in 2026 and for the first time provided a numeric value. Using the benchmark dose method with an uncertainty factor of 400, it derived a temporary safe dose of 0.0275 mg per kilogram body weight per day, about 2 mg daily for a 70 kg person.

This value has a narrow scope. It applies only to supplements with cannabidiol purity of at least 98%, without nanoparticles, produced by a process recognized as safe, and with excluded genotoxicity. It does not transfer to other product forms, especially full-spectrum extracts with unknown composition.

The most important sentence in the opinion is not a number. The panel states that CBD safety cannot be established for people under 25, pregnant and breastfeeding women, and those taking medications. Gaps identified in 2022 remain due to methodological limitations: protocols without standardization, short observation times, concomitant treatments.

The evidence points to caution. Animal studies show consistent liver toxicity, with liver weight and histopathological changes as sensitive endpoints, and human studies indicate hepatotoxic potential, especially with concomitant drug use. Placental transfer, neurodevelopmental effects after prenatal exposure, and hormonal disruptions were also noted. Immunotoxicity was not studied in included research (EFSA NDA Panel, EFSA Journal 2026).

Does CBD interact with medications?

A safety review by Iffland and Grotenhermen confirmed a favorable adverse effect profile of cannabidiol with drugs used for the same indications but identified interactions as an area needing further research. Most reported symptoms were fatigue, diarrhea, and changes in appetite and body weight (Iffland and Grotenhermen, 2017).

The authors explicitly stated more clinical studies on cannabidiol’s effects on liver enzymes and drug transporters are needed to determine whether these interactions are beneficial or harmful. This is the state of knowledge from the review, not a list of safe combinations, and no patient-specific recommendations can be derived.

EFSA’s 2026 opinion adds a stronger statement: safety cannot be established for people taking medications, and hepatotoxic signals in humans appear with combined treatment. If you take any medication regularly, consulting your doctor or pharmacist is a prerequisite, not a formality.

Absorption variability also matters. Pharmacokinetic studies cited by EFSA show cannabidiol bioavailability depends on product form and whether taken with food. The same milligram number on the label may mean different body exposure, complicating prediction of drug combination effects.

We removed from this article a repeatedly cited Polish internet figure of CBD safety up to 1500 mg daily, attributed to WHO. The document referenced is no longer available at the given address, and the only institutional numeric value is from EFSA’s opinion, which is several hundred times lower.

Who supervises the CBD product market in Poland?

Supervision is divided by product category, not ingredient. The Main Pharmaceutical Inspectorate oversees medicinal products, wholesale trade in narcotics, and pharmacy permits. The State Sanitary Inspection supervises food, dietary supplements, and cosmetics. The Trade Inspection checks labeling, commercial descriptions, and advertising.

The practical effect is this. The same oil falls under sanitary supervision as a supplement and trade supervision as a good, but none of these bodies routinely test the chemical composition of every batch introduced, unlike for medicinal products. Control usually occurs after a complaint, not before sale.

Pharmaceutical supervision is much denser. Wholesale trade in narcotics and psychotropic substances requires a permit from the Main Pharmaceutical Inspector (art. 40 sec. 1 of the Act on Counteracting Drug Addiction), and pharmacies dispense such preparations only on prescription or demand. There is simply no equivalent permit on the store side.

For consumers, one useful rule remains. The institution to report a problem to depends on how the product is classified on the packaging, not on containing cannabidiol. Supplements and cosmetics lead to the sanitary inspection, misleading descriptions or advertising to the trade inspection, and pharmacy products to the pharmaceutical inspection.

What does the August 27, 2026 amendment change?

In the area covered by this article, nothing. The Act of July 3, 2026 amending the Act on Counteracting Drug Addiction and some other acts (Journal of Laws 2026 item 1004) enters into force August 27, 2026, and does not affect the THC threshold, art. 4 definitions, or retail sale rules for cannabis products. We checked its text in the legal acts register.

Changes it actually introduces in the cannabis part concern cultivation and purchase. The deadline for reporting changes in industrial hemp producer data extends from 14 to 30 days (art. 47c sec. 3). Art. 52b adds a new sec. 2: anyone preventing the competent director from inspecting a poppy or industrial hemp purchase entity is subject to a 10,000 PLN fine.

The amendment also adds to art. 45 definitions of own processing and own-use cultivation. The latter means cultivation for products used on one’s own farm, without resale possibility. This clarifies the existing state, not a new ban.

The rest of the act concerns non-consumer matters: substitution treatment, reporting, renaming an EU agency. The sentence worth remembering is short. The text valid August 26, 2026 remains valid August 28, so none of the legal bases here require updating with that date.

What about the Polish CBD market cannot be established today?

More than guides suggest. In preparing this version, we removed several numbers unsupported by any public source: share of products with current certificates of analysis, number of pharmacies authorized to dispense cannabis preparations, number of doctors issuing Rpw prescriptions, annual number of fulfilled prescriptions, and amount of raw material issued.

Prices are similar. Circulating ranges for pharmacy flower per gram, consultation costs, and monthly therapy costs do not come from any register or list to which readers could be referred. The price of magistral preparations depends on pharmacy pricing and prescription composition, so giving one number for the whole country would be fabrication with a pretense of precision.

It is also impossible to base on a solid source the share of domestic production in pharmacy supply or forecasts for coming years. Since the law allows cultivation for pharmacy raw material only for a research institute with a permit from the Main Pharmaceutical Inspector, any market share listings of private producers would first require clarifying their legal basis.

We also changed how we cite regulations. Instead of a link to a legal acts search engine, we give the Journal of Laws designation, article, and paragraph, because the search engine address does not guarantee the reader sees the text, while the designation allows finding it in any register. Every national basis listed above was read from consolidated texts or amending acts, not from commentary.

We leave this gap described rather than filling it with a number that sounds credible. A regulation text giving unverifiable data repeats exactly the error it accuses manufacturers of unreliable labels of.

Frequently Asked Questions

Does a CBD product from a store have to have a certificate of analysis?

No. Regulations do not impose on the manufacturer of a supplement or cosmetic the obligation to test every batch in an accredited laboratory. The certificate is voluntary, so its absence does not break the law, but deprives you of the only proof that the label declaration matches the content of the package.

What is the THC threshold for industrial hemp?

The threshold is 0.3% and applies to the plant, not the finished product. It is calculated as the sum of delta-9-THC and tetrahydrocannabinolic acid in the flowering or fruiting tops, expressed on a dry mass basis, rounded to one decimal place (art. 4 point 5 of the Act on Counteracting Drug Addiction).

Can you get a prescription for cannabis flower via teleconsultation?

Usually not. The regulation requires a personal examination of the patient before issuing a prescription for a preparation from Annex 2, and cannabis other than industrial hemp and cannabis resin are on that list. The exception applies to a primary care physician continuing already started treatment.

What CBD dose does EFSA currently consider safe?

In 2026, the EFSA panel derived a temporary safe dose of 0.0275 mg per kilogram of body weight per day, about 2 mg for a 70 kg person. This applies only to supplements with cannabidiol purity of at least 98%, without nanoparticles.

Do studies confirm CBD efficacy in neuropathic pain?

No. The 2026 Cochrane review update included 21 studies and 2187 participants and found no clear evidence for 50% pain relief over placebo for cannabidiol-dominant preparations. The certainty of evidence was rated very low.

Who supervises CBD products in Poland?

Supervision is divided. The Main Pharmaceutical Inspectorate is responsible for medicinal products and pharmacy raw materials, the State Sanitary Inspection for food, supplements, and cosmetics, and the Trade Inspection for labeling and advertising. None of these bodies routinely test the composition of every batch.

Summary

Regulation of cannabis products in Poland is not one regulation but three parallel ones. Pharmacy flower is based on art. 33a of the Act on Counteracting Drug Addiction and an office permit; its prescription requires personal examination and covers up to 90 days of use, fulfilled within 30 days. Store products fall under food or cosmetics regulations, where batch testing is the manufacturer’s decision.

Three things to remember from the scientific part. The 0.3% threshold applies to the plant and is the sum of THC and THCA. Evidence for cannabidiol efficacy in neuropathic pain is, according to the 2026 Cochrane update, very uncertain. EFSA gives a temporary safe dose of about 2 mg daily for a 70 kg person and states safety cannot be established for people under 25, pregnant or breastfeeding women, and those taking medications.

If you seek a consumer product, not medicinal, and want to compare declarations with certificates, start with the oils category in the Bucha store.

This article is for informational and educational purposes and does not constitute legal advice. The legal status described is valid on the publication date: cannabis regulations may change. Consult a lawyer or current legal acts before making decisions.

Author: Michał Waluk · Published: 2026-05-10 · Updated: 2026-08-10